Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Regemat 3D
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==Summary== Regemat3D develops bioprinters and bioreactors that allow researchers to print cartilage, meniscus, muscle tissue and spinal cord, with the ultimate aim of improving patients quality of life. 2021 Revenue reached: β¬890k and EBITDA β¬11k (Revenue CAGR 2016-21 grew by +36%) * Global bioprinting market is estimated to be worth approx $1.6bn by 2024. * Technology based in bioprinters and bioreactors * Collaboration project with Rovi Pharmaceutics (Market Cap β¬3.8bn) * The CEO is the first person in Spain to have a PhD in 3D Bioprinting
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)